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Abstract: DNA-templated organic synthesis enables the translation of DNA sequences into synthetic small-
molecule libraries suitable for in vitro selection. Previously, we described the DNA-templated multistep
synthesis of a 13 824-membered small-molecule macrocycle library. Here, we report the discovery of small
molecules that modulate the activity of kinase enzymes through the in vitro selection of this DNA-templated
small-molecule macrocycle library against 36 biomedically relevant protein targets. DNA encoding selection
survivors was ampliﬁed by PCR and identiﬁed by ultra-high-throughput DNA sequencing. Macrocycles
corresponding to DNA sequences enriched upon selection against several protein kinases were synthesized
on a multimilligram scale. In vitro assays revealed that these macrocycles inhibit (or activate) the kinases
against which they were selected with IC50 values as low as 680 nM. We characterized in depth a family
of macrocycles enriched upon selection against Src kinase, and showed that inhibition was highly dependent
on the identity of macrocycle building blocks as well as on backbone conformation. Two macrocycles in
this family exhibited unusually strong Src inhibition selectivity even among kinases closely related to Src.
One macrocycle was found to activate, rather than inhibit, its target kinase, VEGFR2. Taken together,
these results establish the use of DNA-templated synthesis and in vitro selection to discover small molecules
that modulate enzyme activities, and also reveal a new scaffold for selective ATP-competitive kinase
inhibition.
Introduction
The discovery of small molecules capable of selectively
modulating the activity of biological targets remains a central
challenge of chemistry and chemical biology. Such small
molecules are commonly discovered through combinatorial
1,2
or diversity-oriented
3 synthesis and high-throughput screening
4
(HTS). In contrast, functional molecules emerge in nature
through iterated cycles of translation, selection, and ampliﬁcation
with mutation.
5-8 While scientists have applied components of
biological evolution to generate DNA, RNA, and protein
molecules with tailor-made catalytic or binding properties, this
approach has traditionally been restricted to molecules whose
structures are compatible with biosynthetic machinery.
9-16 Our
group has developed DNA-templated organic synthesis as a
method for translating DNA sequences into synthetic small
molecules
17-25 and synthetic polymers
26-28 that can be sub-
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648.
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(10) Forster, A. C.; Tan, Z.; Tan, M. N.; Nalam, H.; Lin, H.; Qu, H.;
Cornish, V. W.; Blacklow, S. C. Proc. Natl. Acad. Sci. U.S.A. 2003,
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(24) Tse, B. N.; Snyder, T. M.; Shen, Y. S.; Liu, D. R. J. Am. Chem. Soc.
2008, 130, 15611–15626.
(25) Li, X.; Liu, D. R. Angew. Chem., Int. Ed. 2004, 43, 4848–4870.
Published on Web 08/03/2010
10.1021/ja104903x  2010 American Chemical Society J. AM. CHEM. SOC. 2010, 132, 11779–11791 9 11779jected to in Vitro selection for desired properties.
17,20,23,28,29
Several related approaches to generate and evaluate DNA-
encoded small-molecule libraries have also been used success-
fully in academic
30-38 and industrial settings.
39,40
Macrocycles are particularly attractive candidates for the
discovery of biologically active small molecules because their
rigid scaffolds can decrease the entropic cost of target binding
and limit access to nonbinding conformations, resulting in higher
afﬁnity and greater binding speciﬁcity than their corresponding
linear counterparts.
41 In addition, macrocyclic peptide-like
structures can offer advantages for applications in cell culture
and in ViVo over their linear analogues, since they can possess
higher bioavailability, membrane permeability, and resistance
to in ViVo degradation.
41 While synthesizing macrocyclic
structures especially in a library format can be challenging,
42,43
we speculated that features of DNA-templated synthesis includ-
ing compatibility with aqueous solvents, extremely low (nM)
reactant concentrations, and the ability of base pairing to hold
together relevant reactants at high effective molarities would
promote efﬁcient macrocylization. Indeed, these features enabled
the DNA-templated synthesis and model in Vitro selection of a
pilot library of 65 macrocycles.
20 Subsequent advances in DNA
template design and DNA-templated synthesis methods enabled
the preparation and characterization of a larger 13 824-
membered DNA-templated macrocycle library.
24
Here, we report the discovery and characterization of selective
inhibitors of protein kinases from the in Vitro selection of the
13 824-membered DNA-templated macrocycle library against
a panel of therapeutically relevant protein targets. In contrast
to typical HTS technologies, selections enable the simultaneous
evaluation of small-molecule libraries in one pot regardless of
library size, obviating the signiﬁcant time and infrastructure
demands of screening. Moreover, the simplicity of these
selections enables large numbers of them to be executed in
parallel by a single researcher. The in Vitro selection effort
summarized in this work represents the evaluation of ∼497 000
potential protein-small molecule interactions by a single re-
searcher yet only required a modest time investment and simple
equipment. To facilitate the analysis of such a large number of
selection outcomes in a cost-effective and efﬁcient manner, we
used PCR-installed DNA barcodes in conjunction with ultra-
high-throughput (“deep”) DNA sequencing.
The Src kinase inhibitors discovered through this approach
represent, to our knowledge, the ﬁrst examples of synthetic
peptidic macrocycles that inhibit protein kinase activity in an
ATP-competitive manner. Some of the Src-inhibiting macro-
cycles exhibited unusual selectivity for Src when screened
against a representative panel of human protein kinases. We
also discovered macrocycles that activate VEGFR2 kinase and
that inhibit Akt3, MAPKAPK2, p38R, and Pim1 kinases.
Together, these results demonstrate that DNA-templated library
synthesis coupled with in Vitro selection can lead to the
discovery of protein-binding synthetic small molecules that
include enzyme inhibitors and activators. These results also
reveal two novel and synthetically versatile scaffolds for the
selective inhibition of Src-family protein kinases.
Results
Previous work in our group has established that DNA-linked
small molecules with protein binding afﬁnity can be enriched
from complex mixtures containing predominantly nonbinding
DNA-linked small molecules,
20,29 and that a library of 13 824
DNA templates can be translated into a corresponding library
of synthetic macrocycles through three DNA-templated synthesis
reactions.
24 In this work, we integrate these capabilities into a
broad effort to discover and characterize synthetic small-
molecule macrocycles that inhibit or activate protein targets of
interest.
Validating the in Vitro Selection of DNA-Linked Small
Molecules That Bind Proteins Fused to GST. Prior to undertak-
ing library selections, we ﬁrst validated a general and efﬁcient
in Vitro selection strategy that would support selections against
many different protein targets. We sought to improve our earlier
in Vitro selection efforts that used proteins covalently bound to
beads
29 by implementing a strategy that would not perturb the
covalent structure of the target protein upon immobilization.
Glutathione-S-transferase (GST) fusions of many biomedically
relevant proteins are readily available, typically retain native
function, and can be immobilized in a deﬁned way using
glutathione-linked resin. Furthermore, library members that bind
targets presented in this manner can be speciﬁcally eluted under
mild conditions with free glutathione. This elution strategy
should minimize the enrichment of library members that bind
molecules other than the target of interest, such as resins or
resin-bound linkers.
We tested the ability of immobilized GST-fusion proteins to
enrich known small-molecule ligands covalently linked to DNA
oligonucleotides in several mock selections using GST-tagged
MDM2, FKBP, Bcl-xL, cRaf-1, and HSP90 as protein targets.
In brief, a known small-molecule ligand linked to DNA (the
positive control) was combined with a 100- to 10 000-fold molar
excess of a nonbinding DNA sequence (the negative control).
The negative and positive control sequences were of identical
length and shared common PCR primer-binding sequences. The
mixture was incubated with the corresponding protein target
immobilized on glutathione-linked beads. Following several
(26) Kleiner, R. E.; Brudno, Y.; Birnbau, M. E.; Liu, D. R. J. Am. Chem.
Soc. 2008, 130, 4646–4659.
(27) Rosenbaum, D. M.; Liu, D. R. J. Am. Chem. Soc. 2003, 125, 13924–
13925.
(28) Brudno, Y.; Birnbaum, M. E.; Kleiner, R. E.; Liu, D. R. Nat. Chem.
Biol. 2010, 6, 148–155.
(29) Doyon, J. B.; Snyder, T. M.; Liu, D. R. J. Am. Chem. Soc. 2003, 125,
12372–12373.
(30) Dumelin, C. E.; Scheuermann, J.; Melkko, S.; Neri, D. Bioconjugate
Chem. 2006, 17, 366–370.
(31) Halpin, D. R.; Harbury, P. B. PLoS Biol. 2004, 2, 1015–1021.
(32) Halpin, D. R.; Harbury, P. B. PLoS Biol. 2004, 2, 1022–1030.
(33) Halpin, D. R.; Lee, J. A.; Wrenn, S. J.; Harbury, P. B. PLoS Biol.
2004, 2, 1031–1038.
(34) Melkko, S.; Scheuermann, J.; Dumelin, C. E.; Neri, D. Nat. Biotechnol.
2004, 22, 568–574.
(35) Melkko, S.; Zhang, Y.; Dumelin, C. E.; Scheuermann, J.; Neri, D.
Angew. Chem., Int. Ed. 2007, 46, 4671–4674.
(36) Scheuermann, J.; Dumelin, C. E.; Melkko, S.; Zhang, Y.; Mannocci,
L.; Jaggi, M.; Sobek, J.; Neri, D. Bioconjugate Chem. 2008, 19, 778–
785.
(37) Wrenn, S. J.; Weisinger, R. M.; Halpin, D. R.; Harbury, P. B. J. Am.
Chem. Soc. 2007, 129, 13137–13143.
(38) Buller, F.; Steiner, M.; Scheuermann, J.; Mannocci, L.; Nissen, I.;
Kohler, M.; Beisel, C.; Neri, D. Bioorg. Med. Chem. Lett. 2010, 20,
4188–4192.
(39) Clark, M. A.; et al. Nat. Chem. Biol. 2009, 5, 647–654.
(40) Hansen, M. H.; Blakskjaer, P.; Petersen, L. K.; Hansen, T. H.; Hojfeldt,
J. W.; Gothelf, K. V.; Hansen, N. J. V. J. Am. Chem. Soc. 2009, 131,
1322–1327.
(41) Driggers, E. M.; Hale, S. P.; Lee, J.; Terrett, N. K. Nat. ReV. Drug
DiscoVery 2008, 7, 608–624.
(42) Hruby, V.; Ahn, J. M.; Liao, S. Curr. Opin. Chem. Biol. 1997, 1,
114–119.
(43) Spatola, A. F.; Romanovskis, P. In Combinatorial Peptide and
Nonpeptide Libraries: A Handbook; Jung, G., Ed.; VCH Publishers:
New York, 1996; pp 327-347.
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to the resin were eluted with free glutathione and subjected to
PCR ampliﬁcation or carried through to another round of
selection. The ratio of positive control DNA to nonbinding DNA
was measured using a restriction endonuclease
29 or by qPCR.
44-46
After only one round of selection, we observed substantial (∼10-
to 1000-fold) enrichment of the positive control-encoding DNA
sequence against all ﬁve GST-linked protein targets (Figure S1
and Table S1). These results conﬁrmed our ability to enrich
DNA-linked small-molecule protein ligands using immobilized
GST-tagged proteins.
In Vitro Selection of 13 824 DNA-Templated Small-
Molecule Macrocycles. As previously described, the DNA-
templated small-molecule macrocycle library used in this in Vitro
selection effort was generated in three DNA-templated reactions
followed by a nontemplated Wittig macrocyclization reaction to
generate the ﬁnal product (Figure 1a).
20,24 Each DNA-templated
library synthesis step relied on a set of 12 DNA-linked building
blocks comprising both natural and non-natural amino acids
(Figure 1b).
24 These 36 building blocks together with eight
variable diamino-acid scaffolds (Figure 1b) result in a theoretical
diversity of 13 824 DNA-templated macrocycles. The ﬁdelity of
DNA-templated macrocycle library synthesis was extensively
characterized by high-resolution LC-MS analysis of sublibraries
and by gel electrophoresis and LC-MS analysis of reactions
containing all possible building blocks and scaffolds as previ-
ously described.
24
We chose a diverse set of biomedically relevant protein targets
including protein kinases, protein phosphatases, small GTPases,
PDZ domains, SH2 domains, nuclear receptors, and antiapop-
totic proteins for in Vitro selection (Table 1). Multiple repre-
sentatives were chosen from each protein class so that we could
compare selection results within protein families. In total, we
performed a single round of in Vitro selection against 36 protein
targets. Additionally, we also performed a selection for binding
to GST (with no fused target protein) immobilized on glu-
tathione-linked resin. Although successive rounds of selection
(with or without DNA ampliﬁcation and translation between
rounds) can multiply net enrichment factors,
29 we hypothesized
that recent advances in ultra-high-throughput DNA sequencing
would enable even modest enrichment factors to be robustly
detected, and the ﬁndings in this work are the result of a single
round of selection on each protein target.
Following in Vitro selection, DNA templates linked to target-
binding macrocycles were ampliﬁed in PCR reactions using
primers containing “barcode” sequences speciﬁc to each selec-
tion (Figure 2). We also ampliﬁed DNA templates from eight
aliquots of the unselected library to determine the initial
abundance of each library member. A set of 12 ﬁve-base
barcodes used in pairwise combinations provided sufﬁcient
encoding complexity for one round of selection against 36
protein targets, a control selection against immobilized GST,
and eight preselection library samples (Table S2). These
barcodes were designed to differ by at least three bases from
one another so that common DNA sequencing errors would not
preclude barcode assignment. After afﬁnity selection and PCR
ampliﬁcation, barcoded samples were combined in equimolar
amountsandsubmittedforultra-high-throughputDNAsequencing
47,48
as a single sample.
Ultra-High-Throughput DNA Sequencing and Analysis of
Selection Results. To rapidly identify the DNA-linked macro-
cycles that survived target afﬁnity selection, we used Solexa
(Illumina) DNA sequencing technology.
49 Because standard
Solexa sequencing read lengths at the time of this experiment
were shorter than the length of our barcoded library templates
(84 base pairs), the paired-end sequencing method, which
provides both forward and reverse sequencing reads for each
template, was used. We created a PERL computer program to
analyze the large amount of data emerging from high-throughput
sequencing. First, forward and reverse sequence reads were
merged to give complete template sequences. Each complete
DNA sequence was converted into a combination of a barcode
(selection identity) and three codons (building block identities).
Template sequences were then binned by barcode to deconvolute
the results of each selection. The abundance fraction of each
library member was determined within each selection by
counting the number of corresponding DNA sequence occur-
rences and dividing by the total number of interpretable sequence
reads for that selection. Finally, enrichment factors for each
library member were computed by dividing postselection
abundance fraction by preselection abundance fraction. In total,
we received 25.6 million paired forward and reverse sequence
reads from two Solexa sequencing runs. Of these, all four codons
(which require ﬁve out of six correct bases per codon for the
building blocks, and three out of three correct bases per codon
for the scaffold
24) and the selection barcode (which requires
four out of ﬁve correct bases) could be conclusively assigned
for 12.4 million sequences. As a result, we obtained ∼200 000
sequence reads for each selection, and 1.7 million sequence reads
of the preselection library.
Although 100% of the 13 824 possible library DNA sequences
were observed at least once, due to the varying efﬁciencies of
library member synthesis,
24 library members in the preselection
pool were not expected to be present in equal abundance. Since
underrepresented library members are more prone to inaccurate
enrichment factors arising from limited sampling, we evaluated
selection results using scatter plots of enrichment factor versus
sequence counts in order to better identify unusually high
enrichment factors that may arise from macrocycle-target
binding (Figure 3 and Figure S9). Indeed, in most selections,
we observed that those sequences with the fewest sequence
counts exhibited both the largest and the smallest enrichment
factors (Figure 3 and Figure S9), presumably due to statistical
noise among underrepresented library members. The large
number of library members enabled a general relationship
between sequence abundance and typical enrichment levels to
emerge for each selection. Enrichment factors were, therefore,
deemed of interest not only on the basis of their absolute value,
but also only if they fell above the typical enrichment factor
range observed for sequences of that abundance.
Protein Kinase Selection Results. Because most of the
signiﬁcantly enriched DNA sequences arose from selections
against protein kinases, we focused our characterization efforts
on this class of targets. After one round of selection against
Src kinase, macrocycle A11-B1-C5-D7 was enriched 62-fold,
(44) Heid, C. A.; Stevens, J.; Livak, K. J.; Williams, P. M. Genome Res.
1996, 6, 986–994.
(45) Higuchi, R.; Dollinger, G.; Walsh, P. S.; Grifﬁth, P. R. Biotechnology
1992, 10, 413–417.
(46) Livak, K. J.; Flood, S. J. A.; Marmaro, J.; Giusti, W.; Deetz, K. PCR
Methods Appl. 1995, 4, 357–362.
(47) Church, G. M. Sci. Am. 2006, 294, 46–54.
(48) Hall, N. J. Exp. Biol. 2007, 210, 1518–1525.
(49) Bentley, D. R.; Balasubramanian, S.; Swerdlow, H. P.; Smith, G. P.;
Milton, J.; Brown, C. G.; Hall, K. P.; Evers, D. J.; Barnes, C. L.;
Bignell, H. R. Nature 2008, 456, 53–59.
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member in any of the selections described above. We also
identiﬁed macrocycles A11-B1-C10-D7, A11-B1-C3-D7, A10-
B1-C5-D6, A10-B1-C5-D7, A11-B1-C5-D5, A9-B1-C5-D7,
A11-B8-C5-D7, and A11-B8-C10-D7 (Figures 3 and 4) as
enriched between 2- and 7-fold in the Src selection. The
Figure 1. The 13 824-membered DNA-templated small-molecule macrocycle library. (a) Scheme for the multistep DNA-templated synthesis of the macrocycle
library.
24 (b) Amino-acid building blocks used in the library synthesis. Step one building blocks (A1-A12) are shown in red, step two building blocks
(B1-B12) are shown in blue, step three building blocks (C1-C12) are shown in green, and the macrocycle scaffolds (D1-D8) are shown in black.
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similarity among these molecules, and lack of enrichment of
these macrocycles in the other eight kinase selections performed
(Table 2), collectively suggested that this class of molecules
may correspond to authentic Src ligands that are selective for
binding to Src over other protein kinases.
We also identiﬁed two additional families of macrocycles
enriched in selections against several other kinase targets.
Macrocycles A10-Y-C11-D5 (where Y ) B1 or B8) were
enriched against Akt3, MAPKAPK2, Pim1, and VEGFR2
(Figure 5). Macrocycles A12-B8-C10-X (where X ) D1-D8)
exhibited unusually high enrichment factors in the MAPKAPK2
and Pim1 selections (Figure 5). While we were encouraged by
the ability of these molecules to bind similar targets, the high
degree of hydrophobicity of the building blocks in these
macrocycles raised the possibility that they may bind their
targets in a nonclassical mode.
50,51 Moreover, the enrichment
of macrocycles of structure A12-B8-C10-X appears to be
insensitive to changes in ring size (caused by substitution at
the “D” scaffold position) that we anticipated would have large
effects on macrocycle conformation, suggesting that these
macrocycles were interacting with their targets in a nonclassical
binding mode.
24 The possibility that these compounds represent
nonspeciﬁc ligands or “promiscuous aggregators”
50,51 is ex-
plicitly examined below.
Solid-Phase Macrocycle Synthesis. To test if the enriched
DNA sequences emerging from selection correspond to mac-
rocycles with target-binding or target-inhibiting activities, we
synthesized the corresponding macrocycles on multimilligram
scale using Fmoc solid-phase peptide synthesis (Scheme 1).
20
In brief, NovaPEG Rink amide resin (Merck) was coupled to a
differentially protected diamino acid building block. An iso-
propylidene-protected tartrate monomethyl ester was reacted
with one amine, and a tripeptide was synthesized on the other
amine using three cycles of Fmoc peptide synthesis. After
generating the phosphonium salt on resin, we cleaved the
macrocyclization precursor from resin using strong acid. This
cleavage reaction simultaneously generated a carboxamide at
the C-terminus and also revealed the tartrate diol. After HPLC
puriﬁcation and LC/MS characterization of the linear product,
we oxidiatively cleaved the diol to reveal an aldehyde and
effected Wittig cyclization by raising the pH of the solution to
generate a phosphonium ylide. Macrocycle syntheses typically
yielded two HPLC-separable isomers that were characterized
as the desired cis and trans macrocycles using NMR spectros-
copy and high-resolution mass spectrometry (Table S3). In total,
27 macrocycles corresponding to enriched DNA sequences were
synthesized on 1-3 mg scale using this route. Overall yields
for each 14-step synthesis (13 solid-phase steps and one solution-
phase step) ranged from 1-12%.
Macrocycles Selected for Binding to Src Inhibit Src
Kinase Activity. Nine macrocycles enriched in the Src selection
(Figure 4) and synthesized as described above were assayed in
Vitro for the ability to inhibit Src kinase activity. Kinase activity
was assayed in the presence of varying concentrations of
macrocycle using the FRET-based Z′-LYTE assay (Invitrogen).
Although our selections did not explicitly select for target
inhibition, all but one of the nine macrocycles tested inhibited
Src kinase activity (Table 3 and Figure S2). All of the assayed
macrocycles with Src selection enrichment factors g4-fold
exhibited IC50 values in the range of ∼500 nM to 10 µM. The
most potent molecules, macrocycles trans-A10-B1-C5-D6 and
cis-A11-B1-C5-D7, which share the furylalanine (B1) and
cyclopropylalanine (C5) building blocks, but otherwise display
signiﬁcant structural diversity, inhibited Src with IC50 values
of 680 and 960 nM, respectively (Table 3 and Figure S2). We
consistently observed large differences in potency between
macrocycle cis and trans stereoisomers (Table 3), highlighting
the importance of macrocycle stereochemistry and conformation
for activity. For example, the cis and trans stereoisomers of
macrocycles A11-B1-C5-D7 and A10-B1-C5-D6 exhibited a
∼10-fold difference in potency (Table 3). Likewise, variants
of highly enriched macrocycles such as A11-B1-C5-D7 (62-
(50) Shoichet, B. K. J. Med. Chem. 2006, 49, 7274–7277.
(51) Coan, K. E.; Shoichet, B. K. J. Am. Chem. Soc. 2008, 130, 9606–
9612.
Table 1. Protein Targets for in Vitro Selection
a
kinases phosphatases GTPases PDZ domains SH2 domains other proteins
Akt3 DEP1 Cdc42 Dvl1-3 Abl1 Bcl-xL
AMPK MEG2 H-Ras-V12 Erbin Abl2 BIR3 (XIAP)
ERBB4 PRL2 RhoA γ1-syntrophin P85RN PPARδ
MK2 Magi1 P85RC
p38R MUPP1 P55γC
MKK6 PAR6B
Pim1 PSD95
Src RGS3
VEGFR2 SAP97
Semcap3
Shank3
a All proteins were purchased or puriﬁed as GST-tagged fusion
proteins (Figure S8).
Figure 2. In Vitro selection of the DNA-templated macrocycle library
against 36 protein targets. Following afﬁnity selection of the library against
an immobilized GST-fused target protein, library members possessing target
afﬁnity were eluted and their attached DNA templates were ampliﬁed by
PCR using DNA primers containing a barcode sequence that uniquely
identiﬁes the protein target. Barcoded PCR amplicons from 36 target protein-
binding selections, one control selection for binding immobilized GST, and
eight aliquots of unselected library were pooled and submitted as one sample
for ultra-high-throughput DNA sequencing.
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methylene group within the macrocycle were not signiﬁcantly
enriched, further suggesting that even closely related library
members can access signiﬁcantly different three-dimensional
structures. Taken together, these results demonstrate the ability
of small molecules emerging from in Vitro selection of DNA-
templated libraries to inhibit with signiﬁcant potency the protein
targets against which they were selected in a manner that is
dependent not only on macrocycle building block identity, but
also on macrocycle stereochemistry.
Macrocycles Selected for Binding to Akt3, MAPKAPK2,
Pim1, and VEGFR2 Modulate Kinase Activity. Macrocycles
A10-B1-C11-D5 and A10-B8-C11-D5 were enriched 2- to
6-fold upon selection for binding Akt3, MAPKAPK2, Pim1,
and VEGFR2 (Figure 5). These two macrocycles are structurally
similar, sharing nitrophenylalanine (A10) and cyclohexylstatine
(C11) building blocks as well as the same lysine scaffold (D5),
and differ only at the B building block with either furylalanine
(B1) or cyclohexylalanine (B8) (Figure 5). For assay purposes,
the macrocycles were synthesized with C-terminal PEG-diamine
linkers to aid solubility, and then tested for the ability to inhibit
Akt3, MAPKAPK2, Pim1 and VEGFR2. The more hydrophobic
of the two compounds, macrocycle cis-A10-B8-C11-D5, inhib-
ited Akt3, MAPKAPK2, Pim1, and p38R-MAPKAPK2 with
IC50 values of 8.7, 6.8, 7.5, and 3.1 µM, respectively (Table 4
and Figure S3). Macrocycle cis-A10-B1-C11-D5 did not inhibit
any of these kinases when assayed with isolated kinase enzymes;
however, we observed inhibition of the p38R-MAPKAPK2
kinase cascade with an IC50 value of 6.4 µM (Table 4 and Figure
S3), suggesting that the molecule may interact with either or
both kinases but only in a conformation that is adopted upon
formation of the p38R-MAPKAPK2 complex. Interestingly, we
observed strong, dose-dependent actiVation of VEGFR2 in the
presence of cis-A10-B1-C11-D5 (Figure S4) with enzyme
activity increasing 70% upon treatment with 10 µM of this
macrocycle and 300% upon treatment with 100 µM compound,
suggesting that this macrocycle may bind to VEGFR2 in a
manner that enhances kinase activity.
We also synthesized and assayed three macrocycles from the
A12-B8-C10-X series that were enriched 2- to 10-fold after in
Vitro selection against MAPKAPK2 and Pim1 (Figure 5). These
macrocycles possess three hydrophobic building blocks, ben-
zoyl-D-phenylalanine (A12), cyclohexylalanine (B8), and styry-
lalanine (C10), with variable scaffold diamino acid building
blocks. Macrocycles A12-B8-C10-D3, enriched 3-fold against
MAPKAPK2 and 3.5-fold against Pim1; A12-B8-C10-D4,
enriched 3-fold against MAPKAPK2 and 10-fold against Pim1;
and A12-B8-C10-D8, enriched 2.5-fold against MAPKAPK2
and 6-fold against Pim1 (Figure 5), were synthesized and
assayed for inhibition of MAPKAPK2, Pim1, and the p38R-
MAPKAPK2 cascade. We observed modest inhibition of these
kinase targets, with the most potent molecules being cis-A12-
B8-C10-D3 against the p38R-MAPKAPK2 cascade (IC50 ) 11
µM) and cis-A12-B8-C10-D8 against Pim1 (IC50 ) 19 µM)
(Figure S5 and Table 4).
Taken together, these results indicate that DNA-templated
macrocycles that are enriched from in Vitro selections for kinase
afﬁnity frequently possess the ability to inhibit protein kinases
with reasonable potency (low- to mid-micromolar IC50 values)
when synthesized and assayed in a non-DNA-linked form.
Among the nine macrocycles chosen based on the magnitude
of their enrichment during Src selection, or based on their
structurally similarity to the highly enriched A11-B1-C5-D7,
we characterized only one enriched macrocycle (A9-B1-C5-
D7) that did not inhibit Src, representing a false positive rate
of 11%. While we characterized only ﬁve molecules from
selections against Akt3, MAPKAPK2, Pim1, and VEGFR2, due
to enrichment of the same molecule against multiple targets,
Figure 3. Analysis of high-throughput sequencing results. Plot of enrichment factor vs sequence abundance for library members after selection for binding
to Src kinase (enrichment vs sequence abundance plots for all other selections performed are shown in Figure S9). The enrichment factor for each library
member in each selection (∼497 000 total possible combinations of library member and target) were calculated as (postselection abundance)/(preselection
abundance) using a PERL script. Each blue or red dot represents the DNA sequence corresponding to a single library member. The structures of macrocycles
1-9 are shown in Figure 4. Enrichment factors for low-abundance library members vary widely due to statistical undersampling. Only enrichment factors
that were substantially higher than background values were considered potential positives (shown in red).
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molecule, macrocycle A10-B9-C11-D5 (B9 ) citrulline), similar
to the validated A10-Y-C11-D5 family of hits, was observed
enriched above background in the Pim1 (3.5-fold enrichment) and
VEGFR2 (2.4-fold enrichment) selections, but did not inhibit either
kinase when assayed in its non-DNA-linked form. In total, we
observed a similarly low false positive rate of 14% (2/14) from
the Akt3, MAPKAPK2, Pim1, and VEGFR2 selections.
Kinase Inhibition Selectivity of Enriched Src-Inhibiting
Macrocycles. We chose to characterize in greater depth mac-
rocycles cis-A11-B1-C5-D7 and trans-A10-B1-C5-D6 (Figure
4 and Table 3) since they represent potent and structurally
diverse inhibitors that are predicted to be selective for Src kinase
based on in Vitro selection results (Table 2). We ﬁrst character-
ized their mode of inhibition. Although the selection used to
identify the inhibitors is agnostic with respect to target binding
Figure 4. Chemical structures of macrocycles exhibiting signiﬁcant enrichment above background and common structural motifs after selection against Src
kinase. Macrocycle numbering corresponds to that used in Figure 3.
Table 2. Enrichment Factors of Positives from the Src Selection in All Protein Kinase Selections Performed
a
a Macrocycle numbering is from Figure 4. Enrichment factors >10 are colored red; those >4 are colored orange; those >2 are colored yellow.
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C5-D6 are ATP-competitive inhibitors (Figure 6 and Figure S6).
We next determined the selectivity of these molecules against
a representative set of human kinases. Although kinase selectiv-
ity can be modest for ATP-competitive inhibitors since the ATP-
binding site is highly conserved among protein kinases,
52-55
our selection data (Table 2) suggested that the Src-inhibiting
macrocycles may exhibit unusual selectivity.
Macrocycle cis-A11-B1-C5-D7 was assayed at 50 µM against
a representative panel of 58 commercially available human
protein kinases including all nine mammalian Src family kinases
(Table S4). For those kinases that displayed signiﬁcant inhibition
(>40%) at 50 µM cis-A11-B1-C5-D7, we reassayed at 5 µM
compound concentration to estimate rough IC50 values and
performed 10-point IC50 titrations for the most potently inhibited
(52) Hanks, S. K.; Hunter, T. FASEB J. 1995, 9, 576–596.
(53) Hanks, S. K.; Quinn, A. M. Methods Enzymol. 1991, 200, 38–62.
(54) Hanks, S. K.; Quinn, A. M.; Hunter, T. Science 1988, 241, 42–52.
(55) Stout, T. J.; Foster, P. G.; Mathews, D. J. Curr. Pharm. Des. 2004,
10, 1069–1082.
Figure 5. Plots of enrichment factor vs sequence abundance for library members after selection for binding to Akt3, MAPKAPK2, Pim1, and VEGFR2.
Macrocycles 10-19 exhibit signiﬁcant enrichment above background.
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score
56 for the macrocycle based on the number of nontarget
proteins exhibiting IC50 values within 10-fold of the 960 nM
IC50 of cis-A11-B1-C5-D7 for Src. Macrocycle cis-A11-B1-
C5-D7 displayed a selectivity score of 0.05, indicating that only
5% of the kinases assayed were inhibited with IC50 values within
10-fold of the IC50 for Src. When judged by similar criteria,
cis-A11-B1-C5-D7 is signiﬁcantly more selective than the
promiscuous ATP-competitive inhibitor staurosporine (selectiv-
ity score ) 0.50), and slightly more selective than two kinase
inhibitor drugs: sorafenib (selectivity score ) 0.10) and dasa-
tanib (selectivity score ) 0.10).
56 The most potently inhibited
proteins other than Src were closely related kinases such as Fgr
(a Src family kinase, IC50 ) 4.0 µM) and RET (a tyrosine kinase,
IC50 ) 5.7 µM), as well as Aurora A, a serine/threonine kinase
which shares close structural homology to Src-family kinases
(IC50 ) 1.7 µM).
57
(56) Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge,
C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen,
P.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.;
Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka,
L. M.; Zarrinkar, P. P. Nat. Biotech. 2008, 26, 127–132.
(57) Cheetham, G. M. T.; Knegtel, R. M. A.; Coll, J. T.; Renwick, S. B.;
Swenson, L.; Weber, P.; Lippke, J. A.; Austen, D. A. J. Biol. Chem.
2002, 277, 42419–42422.
Scheme 1. Milligram-Scale Synthesis of Macrocycle A11-B1-C5-D7
a
a The route was adapted from Gartner et al.
20 Methyl hydrogen 2,3-O-isopropylidene-(L)-tartrate was synthesized as reported by Musich and Rapoport.
70
Table 3. Macrocycles Corresponding to Src Selection Survivors
Inhibit Src Kinase
a
macrocycle Src IC50 (µM)
cis-A11-B1-C5-D7 0.96
trans-A11-B1-C5-D7 12
cis-A11-B1-C10-D7 7.0
trans-A11-B1-C10-D7 21
cis-A11-B1-C3-D7 10
trans-A11-B1-C3-D7 48
cis-A10-B1-C5-D6 7.4
trans-A10-B1-C5-D6 0.68
cis-A10-B1-C5-D7 8.9
trans-A10-B1-C5-D7 1.5
cis-A9-B1-C5-D7 >100
trans-A9-B1-C5-D7 >100
cis-A11-B1-C5-D5 85
trans-A11-B1-C5-D5 >100
cis-A11-B8-C5-D7 36
trans-A11-B8-C5-D7 >100
cis-A11-B8-C10-D7 25
trans-A11-B8-C10-D7 >100
a Src kinase activity was assayed in the presence of increasing
concentrations of macrocycle using the Z′-LYTE assay (Invitrogen).
Table 4. Enriched Macrocycles Inhibit Pim1, MK2, Akt3, and
p38a-MK2
a
macrocycle kinase IC50 (µM)
cis-A10-B1-C11-D5 p38R-MK2 6.5
cis-A10-B1-C11-D5 Pim1 21
cis-A10-B8-C11-D5 Akt3 8.4
cis-A10-B8-C11-D5 MK2 6.1
cis-A10-B8-C11-D5 p38R-MK2 3.4
cis-A10-B8-C11-D5 Pim1 7.3
cis-A12-B8-C10-D3 p38R-MK2 12
cis-A12-B8-C10-D3 Pim1 25
cis-A12-B8-C10-D4 p38R-MK2 20
cis-A12-B8-C10-D4 Pim1 100
cis-A12-B8-C10-D8 MK2 47
cis-A12-B8-C10-D8 p38R-MK2 14
cis-A12-B8-C10-D8 Pim1 17
a Kinase activity was assayed in the presence of increasing
concentrations of macrocycles using Invitrogen’s Z-LYTE assay.
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exhibited exceptional selectivity among Src-like protein kinases
that have traditionally been difﬁcult to distinguish by small-
molecule inhibition (Figure 7). For example, this macrocycle
exhibits >50-fold selectivity for Src over Abl kinase, > 50-fold
selectivity for Src over the Src-family kinases Hck and Fyn,
and >10-fold selectivity for Src over all remaining Src-family
kinases with the exception of Fgr (Figure 7 and Table S4).
Similarly, among the closely related Aurora kinases, we
observed >50-fold selectivity for Aurora A over Aurora B
(Figure 7 and Table S4).
We also investigated the selectivity of the nitrophenylalanine
(A10)-containing macrocycle trans-A10-B1-C5-D6. While it
shares two out of four building blocks in common with cis-
A11-B1-C5-D7 and also inhibits Src in an ATP-competitive
manner, building block composition in this macrocycle is
strikingly different at the A position and the trans stereochem-
istry of the oleﬁn contrasts with the oleﬁn geometry of the active
isomer of A11-B1-C5-D7. The differences between these two
molecules were further revealed upon assays against a kinase
panel, in which trans-A10-B1-C5-D6 exhibited even greater
selectivity for Src than macrocycle cis-A11-B1-C5-D7 (Figure
7). Macrocycle trans-A10-B1-C5-D6 did not signiﬁcantly inhibit
Aurora A, RET, or any of the other Src-family kinases (the
primary kinases beyond Src that are inhibited by cis-A11-B1-
C5-D7) at the concentration tested (5 µM) (Figure 7). Indeed,
of all 44 human kinases against which this macrocycle was
assayed, Src was the only kinase observed to be signiﬁcantly
inhibited by this macrocycle (Figure 7 and Table S5). This level
of Src selectivity is unprecedented among currently available
Src-selective kinase inhibitors such as PP1 and PP2,
58 which
are signiﬁcantly more potent against Src-family members Fyn,
Hck, and Lyn than against Src itself. Taken together, these
results establish that macrocycles emerging from the in Vitro
selection of a DNA-templated small-molecule library include
kinase inhibitors that exhibit unusual selectivity.
SAR Analysis of Src-Inhibiting Macrocycles. We analyzed
the set of macrocycles enriched in the Src selection to develop
basic structure-activity relationships for Src inhibition. Our
selection data shows a strong preference for a small set of
building blocks at each nonscaffold position (Figure 4), sug-
gesting that all three macrocyclic building blocks are important
for binding. To test this hypothesis, we synthesized three
derivatives of macrocycle cis-A11-B1-C5-D7 by systematically
replacing each of the nonscaffold building blocks (positions A,
B, and C) with alanine, in analogy to alanine-scanning mu-
tagenesis of proteins. We assayed the resulting three single-
alanine mutants for Src inhibition and observed that none of
the three mutant macrocycles at 5 µM signiﬁcantly inhibit Src
or the Src-family kinase Fgr (Figure 8a), indicating that all three
building blocks contribute to the kinase inhibition activity of
cis-A11-B1-C5-D7.
To evaluate the importance of the macrocyclic nature of these
molecules for kinase inhibition, we synthesized two diacetylated
linear peptides as linear versions of macrocycles A11-B1-C5-
D7 and A10-B1-C5-D6 (Figure 8b) and assayed their abilities
to inhibit Src. These two compounds are identical to their
corresponding macrocycles with the exception that the oleﬁn
group resulting from Wittig macrocyclization is replaced by two
methyl groups in the linear peptides. Both linear peptides were
virtually inactive against Src kinase, conﬁrming the necessity
of a cyclic scaffold to preorganize these sets of building blocks
(58) Hanke, J. H.; Gardner, J. P.; Dow, R. L.; Changelian, P. S.; Brissette,
W. H.; Weringer, E. J.; Pollok, B. A.; Connelly, P. A. J. Biol. Chem.
1996, 271, 695–701.
Figure 6. Macrocycle cis-A11-B1-C5-D7 is an ATP-competitive inhibitor of Src kinase. (a) The apparent KM of Src for ATP was measured in the presence
of increasing concentrations of macrocycle cis-A11-B1-C5-D7. Kinase activity was measured as in Table 3. (b) The resulting relationship is linear in accord
with the following equation for a classical competitive inhibitor: apparent KM ) KM × (1 + [inhibitor]/Ki).
Figure 7. Selectivity of macrocycles cis-A11-B1-C5-D7 and trans-A10-
B1-C5-D6 among Src-related kinases, including all nine Src-family kinases.
Both macrocycles were assayed at 5 µM concentration against the indicated
kinases. Assays of cis-A11-B1-C5-D7 against Abl and Hck were performed
at 50 µM macrocycle concentration instead of 5 µM. Percent kinase
inhibition values plotted are the average of two independent measurements.
Assay data for Src kinase is from Figure S2 and Table 3. All non-Src assay
points were measured by the Invitrogen Select Screen Proﬁling Service.
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inhibiting the kinase.
Oleﬁn stereochemistry plays a critical role in the ability of
these compounds to inhibit Src kinase activity. Macrocycles
possessing the ornithine(pyrazinylcarbonyl) building block
(A11) and diaminobutyric acid scaffold (D7) are more potent
Src inhibitors in their cis-isomeric form (Table 3). These
macrocycles favor furylalanine (B1) over cyclohexylalanine (B8)
at the B position, as evidenced by the weakened potency of
macrocycles cis-A11-B8-C5-D7 and cis-A11-B8-C10-D7 com-
pared to cis-A11-B1-C5-D7 and cis-A11-B1-C10-D7 (Table 3),
respectively. All of these compounds exhibit hydrophobic
building blocks at the C position, especially cyclopropylalanine
(C5) (Figure 4 and Table 3).
In contrast, macrocycles with nitrophenylalanine (A10) at the
A position are more active Src inhibitors in their trans-isomeric
form (Table 3). The ornithine (D6) scaffold also supports more
potent Src inhibition than the diaminobutyric acid (D7) scaffold
that differs by the loss of a single methylene group (Table 3).
We assayed the importance of the nitrophenylalanine (A10)
building block for Src inhibition by replacing it with phenyla-
lanine in macrocycle trans-A10-B1-C5-D6 to create macrocycle
trans-Phe-B1-C5-D6. This substitution abolished Src inhibition
(Figure 8c), indicating the importance of the nitro group among
A10 macrocycle subfamily kinase inhibitors. Because of the
altered oleﬁn stereochemistry of the nitrophenylalanine (A10)-
containing macrocycles, the difference in macrocycle ring size,
and the structural differences between the nitrophenylalanine
(A10) and ornithine(pyrazinylcarbonyl) (A11) building blocks,
we believe that these two classes of macrocycles interact in
distinct ways with the Src active site. Indeed, modeling the three-
dimensional conformations adopted by cis-A11-B1-C5-D7 and
trans-A10-B1-C5-D6 using an MM2 energy-minimization al-
gorithm (Chem3D, CambridgeSoft) predicts large differences
in both preferred backbone conformation and preferred side-
chain orientation for these two macrocycles (Figure S10). This
hypothesis is further supported by the substantial differences
in kinase selectivity (Figure 7) exhibited by cis-A11-B1-C5-
D7 and trans-A10-B1-C5-D6.
Figure 8. SAR analysis of Src-inhibiting macrocycles. (a) Single-alanine mutants of cis-A11-B1-C5-D7 were assayed against Src-family kinases Src and
Fgr at 5 µM concentration as described previously. (b) Linear diacetylated peptides corresponding to macrocycles A11-B1-C5-D7 and A10-B1-C5-D6 were
synthesized by Fmoc solid-phase peptide synthesis and assayed against Src kinase. (c) Macrocycle trans-Phe-B1-C5-D6 (replacing nitrophenylalanine with
phenylalanine) was assayed against Src as described previously.
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Aggregators. High-throughput screening can result in the
discovery of noncanonical ligands known as promiscuous
aggregators that form colloidal aggregates in aqueous solution
and inhibit enzymes by a nonspeciﬁc sequestration mechanism
rather than through a classical one-to-one binding mode.
50 A
common property of promiscuous aggregators is a steep
dose-response curve that can result from the enzyme concen-
tration in the kinase assay exceeding the Ki of the aggregated
species, which is typically present at signiﬁcantly lower
concentrations than that of the small molecule itself.
50 We
suspected that A10-Y-C11-D5 and A12-B8-C10-X macrocycles
(Figure 5 and Table 4) might be promiscuous aggregators due
to their high hydrophobicity, broad speciﬁcity, and steep
dose-response curves (Figures S3 and S5).
To test this hypothesis, we assayed macrocycle cis-A10-B8-
C11-D5 against Akt3, MAPKAPK2, and Pim1 and assayed
macrocycle cis-A12-B8-C10-D3 against Pim1 while varying the
concentration of kinase in the reactions. If aggregate formation
results in stoichiometric titration of the kinase, the observed
IC50 value should vary linearly with enzyme concentration.
50
Despite their steep dose-response curves, inhibition of MAP-
KAPK2 and Pim1 did not vary with kinase concentration (Figure
S7), suggesting a different mechanism of inhibition. For
example, steep dose-response curves can also be caused by
multisite binding or by a phase transition in the inhibitor that is
coupled with inhibition.
50 In contrast, we observed that inhibition
of Akt3 by cis-A10-B8-C11-D5 varied linearly with the kinase
concentration used in the assay (Figure S7), indicating that this
macrocycle may be inhibiting Akt3 through a promiscuous
aggregator mechanism.
In contrast, the family of Src-inhibiting macrocycles discov-
ered in this work do not exhibit steep dose-response curves
(Figure S2), bind in an ATP-competitive manner (Figure 6 and
Figure S6), and do not vary signiﬁcantly in observed inhibitory
potency as a function of enzyme concentration (Figure S7).
These results collectively indicate that the Src-inhibiting mac-
rocycles described above are not promiscuous aggregators.
Discussion
DNA-encoded small-molecule libraries can be subjected to
simple afﬁnity-based selection using disposable tubes, micro-
gram quantities of immobilized protein targets, and micropipets,
in contrast with the more labor- and infrastructure-intensive
process of conventional high-throughput screening. As a result,
as demonstrated in this work, DNA-encoded small-molecule
ligands for proteins of interest can be revealed in a manner that
is fast, inexpensive, and largely independent of library size.
Here, we subjected a 13 824-membered DNA-templated mac-
rocycle library to 36 protein afﬁnity-based selections in a parallel
manner. These selections collectively queried ∼497 000 protein-
small molecule interactions in a process that required 3 days of
one researcher’s effort to complete.
The parallel, reasonably low-cost (in 2009, ∼$5500) analysis
of the 36 selections was made possible by recent developments
in ultra-high-throughput sequencing technology that provided
millions of sequence reads of sufﬁcient length to span the coding
regions of our library templates. PCR-installed DNA barcodes
enabled all of the selections to be sequenced as one sample
and deconvoluted for analysis by binning sequence data by
barcode. Our results validate the ability of current DNA
sequencing technology to detect even modestly enriched library
members, obviating the need to perform multiple rounds of
selection for the library members characterized in this work.
The low false positive rate among the macrocycles enriched
during selections studied here suggests that the evaluation of
small molecule-protein interactions based on in Vitro selection
and modern DNA sequencing methods is robust. As ultra-high-
throughput DNA sequencing continues to decrease rapidly in
cost and increase in capability, the analysis of in Vitro selections
evaluatingmillionsofpotentialDNA-encodedsmallmoleculestarget
combinations will become increasingly efﬁcient and routine.
After only one round of in Vitro binding selection, high-
throughput sequencing enabled the identiﬁcation of three
families of enriched macrocycles in the protein kinase selections,
despite enrichment factors that were as low as ∼2- to 3-fold.
All three families of macrocycles enriched after selection were
shown to possess the ability to inhibit their target kinase,
although we chose not to further characterize two of the three
macrocycle families due to their modest potencies, promiscuity,
or poor physicochemical properties. In contrast, macrocycles
enriched in the Src selection (which also displayed the largest
enrichment factors of any of our selections) possessed classical
single-site dose response curves with IC50 values as low as 680
nM. The potency of these compounds is promising given that
they emerged from the broad selection of an untargeted 13 824-
membered library.
Consistent with the highly target-speciﬁc in Vitro selection
results, assays of Src-enriched macrocycles against a broad set
of human kinases revealed that these molecules indeed possess
very good overall selectivity among a panel of human kinases.
The speciﬁcity of these macrocycles is especially intriguing since
these macrocycles are ATP-competitive inhibitors and the ATP-
binding site is highly conserved among protein kinases.
52-54
Furthermore, in addition to possessing good overall selectivity,
the molecules were exceptionally selective among kinases that
have been traditionally very difﬁcult to distinguish by small-
molecule inhibitors. For example, Src and Abl are two closely
related nonreceptor tyrosine kinases that have exhibited very
similar small-molecule binding speciﬁcities.
59-62 Toward the
goal of distinguishing Src and Abl using a small molecule, Maly
and co-workers
63 recently generated bivalent kinase inhibitors
that rely on peptidic recognition outside of the ATP-binding
cleft to generate binding selectivity. Macrocycle A11-B1-C5-
D7 displays >50-fold selectivity for Src over Abl kinase while
binding in an ATP-competitive manner. We also observed >100-
fold selectivity for Aurora A among the closely related Aurora
family of serine/threonine protein kinases.
64 Most reported small
molecule Aurora A inhibitors also inhibit Aurora B and/or
Aurora C with comparable afﬁnity,
65-68 although examples of
Aurora A selective inhibitors have begun to emerge.
69
Macrocycle trans-A10-B1-C5-D6 exhibited even better se-
lectivity for Src, with no signiﬁcant off-target inhibition in the
panel of 44 human kinases against which this compound was
(59) Azam, M.; Nardi, V.; Shakespeare, W. C.; Metcalf, C. A., III; Bohacek,
R. S.; Wang, Y.; Sundaramoorthi, R.; Sliz, P.; Veach, D. R.;
Bornmann, W. G.; Clarkson, B.; Dalgarno, D. C.; Sawyer, T. K.;
Daley, G. Q. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 9244–9249.
(60) Das, J.; et al. J. Med. Chem. 2006, 49, 6819–6832.
(61) Golas, J. M.; Lucas, J.; Etienne, C.; Golas, J.; Discafani, C.; Sridharan,
L.; Boghaert, E.; Arndt, K.; Ye, F.; Boschelli, D. H.; Li, F.; Titsch,
C.; Huselton, C.; Chaudary, I.; Boschelli, F. Cancer Res. 2005, 65,
5358–5364.
(62) Tatton, L.; Morley, G. M.; Chopra, R.; Khwaja, A. J. Biol. Chem.
2003, 278, 4847–4853.
(63) Hill, Z. B.; Gayani, B.; Perara, K.; Maly, D. J. J. Am. Chem. Soc.
2009, 131, 6686–6688.
(64) Fu, J.; Bian, M.; Jian, Q.; Zhang, C. Mol. Cancer Res. 2007, 5, 1–10.
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kinases. The generation of small molecules that are selective
among the Src-family kinases has posed a signiﬁcant challenge
to academic and pharmaceutical drug-discovery efforts, and the
new class of macrocyclic kinase inhibitors described here
represent promising starting points for future probe or thera-
peutic development efforts.
It is tempting to speculate that the observed selectivity arises
at least in part from the design of the library to contain rigid
macrocyclic structures with a high ratio of atoms derived from
varying building blocks to atoms shared in common by all
library members. Kinase selectivity may also result from the
larger size of these molecules compared with traditional ATP-
competitive kinase inhibitors; the presence of additional groups
may support interactions both inside and outside of the ATP-
binding site. The macrocyclic kinase inhibitors discovered in
this work share very few chemical features with classical ATP-
competitive kinase inhibitors, which are typically planar het-
erocycles based on adenine. In contrast, our peptidic macrocy-
cles contain several stereocenters and can adopt distinct three-
dimensional conformations required for selective target binding.
These ﬁndings also demonstrate that changes in building block
composition that do not abrogate Src inhibition can modulate
the selectivity of these macrocycles among human kinases.
Conclusion
We have completed a large-scale in Vitro selection effort of
a DNA-templated small-molecule macrocycle library against a
panel of 36 diverse protein targets. The selections yielded a
new molecular scaffold for Src kinase inhibition that exhibits
well-deﬁned structure-activity relationships and exceptional
selectivity among human kinases. These ﬁndings validate the
use of DNA-templated libraries integrated with in Vitro selection
for the discovery of synthetic small molecules with the ability
to potently and selectively modulate the activity of protein
targets, and also reveal promising compounds for the further
development of selective and potent molecules that can modulate
the function of cellular kinases.
Materials and Methods
In Vitro Selections with Known Protein-Binding Ligands. A
stock solution of GST-labeled protein target was diluted in protein-
binding buffer (50 mM Tris-HCl, pH 7.5, 50 mM NaCl, 10 mM
 -mercaptoethanol) to a ﬁnal concentration of 1 µM. The protein
target (200 pmol) was incubated with 2 µL of MagneGST
(Promega) glutathione-linked magnetic particles for1ha t4°C
with gentle shaking. The beads were washed three times with 100
µL of TBST buffer supplemented with 1 M NaCl, followed by
two washes with 300 µL of protein-binding buffer. The beads were
then diluted in 20 µL selection buffer (TBST, 3 mg/mL yeast tRNA,
1 mM DTT) and 10 µL of resulting protein bead solution was
combined with 1 pmol of a nonbinding DNA sequence and 1/10,
1/100, 1/1000, or 1/10 000 pmol of the known protein-binding
ligand conjugated to DNA. After removing unbound molecules,
the beads were washed three times with 200 µL of selection buffer,
and bound molecules were eluted in 20 µL of 0.1 mM glutathione
in 50 mM Tris pH 8.0 buffer for 15 min. Of this eluant, 5 µL was
subjected to PCR ampliﬁcation.
Positive Control Selection Analysis. Positive-control selections
were analyzed using either a Taqman qPCR assay or restriction-
endonuclease digestion. Taqman qPCR was performed according
to the manufacturer’s protocols. For restriction-endonuclease
analysis, 20 µL of PCR reaction were combined with 5 units of
EarI restriction endonuclease (NEB), and incubated for2ha t3 7
°C. Digested PCR amplicons were separated by agarose gel
electrophoresis and stained with EtBr. The ratio of digested to
undigested DNA was determined by ethidium bromide staining and
densitometry using UV light.
In Vitro Selections with the DNA-Templated Macrocycle
Library. In Vitro selections of the 13 824-membered library were
conducted exactly as described above for the positive control
selections. For each selection, 5 pmol of library was used. PCR
ampliﬁcation of selection survivors was performed with 5′-barcoded
forward and reverse primers. Barcoded PCR amplicons were
quantitated using Picogreen dsDNA quantitation reagent (Invitro-
gen), mixed in equimolar amounts, and submitted for high-
throughput DNA sequencing.
Kinase Assays. Src IC50 determinations and single-point inhibi-
tion measurements were performed using Invitrogen’s Z′-LYTE
Tyr 02 assay kit according to the manufacturer’s protocols. All
kinase assays were performed at ATP concentrations near KM,ATP
values, except where noted otherwise. Active human Src kinase
was obtained from Millipore. For kinome proﬁling and IC50
determinations against non-Src kinases, compounds were submitted
to Invitrogen’s SelectScreen Kinase Proﬁling Service.
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